M0237 Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
Short descriptor: Intrav inf, toci, first dose
Look up M0237 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.
M0237 is the HCPCS Level II code for Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose (2026). It belongs to Section M — Medical Services. Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Vaccinations.
Classification & CMS Attributes
- Section
- M: Medical Services
- Medicare Coverage
- Carrier judgment (code C)
- Part B Pricing
- Vaccinations (indicator 54)
- Type of Service
- Pneumococcal/flu/hepatitis B vaccine
- Effective Date
- 2025-01-24
- 2026 Maintenance
- No change this year
References
Cite This Page
Reference M0237 with the canonical source and edition:
M0237 — Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/M0237
Canonical URL: https://icd10codingpro.com/hcpcs-codes/M0237